TipRanks
Go Ultimate55% OFF

Chia Tai Enterprises International (CAIHF) AI Stock Analysis

CAIHF

Chia Tai Enterprises International

(Other OTC:CAIHF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue and Profitability ReboundThe sharp 2025 revenue rebound, together with improved net and operating margins, shows that the business can restore earnings when operating conditions improve. If this performance is sustained, greater scale and profitability should strengthen reinvestment capacity and competitive resilience.
Negative Factors
Gross Margin CompressionThe sustained decline in gross margin versus earlier years indicates weaker pricing, product mix, or cost absorption, even after the recent earnings rebound. Lower gross profitability reduces the buffer available to absorb cost increases and makes future operating performance more sensitive to execution.

Chia Tai Enterprises International (CAIHF) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%250%300%CAIHF+256.07%SPY+13.13%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
$270.48M
Dividend Yield
―
Average Volume (3M)
240
Price to Earnings (P/E)
10.3
Beta (1Y)
9.73
Revenue Growth
-18.95%
EPS Growth
-6.95%
Country
US
Employees
1,000
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Chia Tai Enterprises International Business Overview & Revenue Model

Company Description

Chia Tai Enterprises International Limited primarily produces and distributes chlortetracycline (CTC) and related goods. Its extensive international reach covers Mainland China, the Asia Pacific region, the Americas, and Europe. The company's operati...

Chia Tai Enterprises International Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CAIHF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:3933HK:393375OutperformHKD 13.46B20.803.12%4.38%-12.86%-83.10%
HK:0950HK:095068NeutralHKD 606.50M3.648.02%5.61%7.05%22.46%
HK:0512HK:051267NeutralHKD 15.30B13.456.61%3.92%7.35%-45.49%
HK:0897HK:089759NeutralHKD 401.18M100.000.34%―-8.30%-44.44%
HK:0570HK:057053NeutralHKD 5.89B-4.80-4.98%0.30%-15.80%-298.94%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%100%200%CAIHFHK:3933HK:0570HK:0897HK:0950HK:0512Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
CAIHF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CAIHFChia Tai Enterprises International 1.000.72256.07%
HK:3933The United Laboratories International6.83-5.39-44.12%
HK:0570China Traditional Chinese Medicine Holdings Co 1.17-1.14-49.35%
HK:0897Wai Yuen Tong Medicine Holdings Limited0.36-0.09-20.00%
HK:0950Lee's Pharmaceutical Holdings Limited1.03-0.73-41.41%
HK:0512Grand Pharmaceutical Group Limited4.31-4.16-49.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.